<html lang='en'><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>'Big Money Makers': Here's What Covid-19 Vaccines Are Worth to Big Pharma</title></head><body><h1>'Big Money Makers': Here's What Covid-19 Vaccines Are Worth to Big Pharma</h1><p>'Big Money Makers': Here's What Covid-19 Vaccines Are Worth to Big Pharma</p><p>&nbsp;&nbsp;&nbsp;&nbsp;The various Covid-19 vaccines currently being distributed around the globe have the potential to end the worst pandemic in a century.They also will mean hundreds of billions dollars in sales for the pharmaceutical companies that make them.</p><p>&nbsp;&nbsp;&nbsp;Despite being priced at less than $20 per dose, Pfizer (PFE) expects sales of the vaccine it developed with BioNTech (BNTX) to total about $15 billion by the end of this year, with a profit margin of nearly 30%.</p><p>&nbsp;&nbsp;&nbsp;Vaccines are typically not the most profitable products in the Big Pharma catalog, especially compared to drugs used to treat chronic conditions.</p><p>&nbsp;&nbsp;&nbsp;'Flu vaccines on balance are a lower margin business,' said Seamus Fernandez, senior managing director at Guggenheim Securities.There are of course exceptions — including the Prevnar vaccine that protects the elderly from pneumococcal pneumonia, which Fernandez describes as 'extremely lucrative' for Pfizer.And the drug maker’s Covid vaccine is likely to be an even a bigger money maker.</p><p>&nbsp;&nbsp;&nbsp;Developing the vaccines was a gamble for the all the companies that tried, even with most drug makers accepting government grands.</p><p>&nbsp;&nbsp;&nbsp;'It would have been a terrible business if the vaccine had failed.It would have been a write off,' Fernandez said.'Obviously for Pfizer and Moderna (MRNA) and Johnson Johnson, it succeeded pretty spectacularly.'</p><p>&nbsp;&nbsp;&nbsp;Although Johnson Johnson (JNJ) has said it will provide the vaccine on a not-for-profit basis as long as the world continues suffering from the pandemic, that doesn’t mean the company won’t ever make money from it.</p><p>&nbsp;&nbsp;&nbsp;That’s because there is an assumption among experts and executives at the drug companies that, even after the pandemic has passed, people will need to receive booster shots to protect themselves from new variants.</p><p>&nbsp;&nbsp;&nbsp;'Genetic mutations occur naturally during virus replication and spread,' Pfizer CEO Albert Bourla said in his most recent call with analysts.'There is an increasingly probable scenario when it could become necessary within the next few years to boost COVID-19 vaccinated patients with a vaccine encoding the spike variant.'</p><p><p><strong><i>Posted On: </i></strong>2021-03-13T00:00:00<br></p></p><p><p><strong>Content Date:</strong>&nbsp;2021-03-13</p><p><strong>Download Date:</strong>&nbsp;2021-05-30</p><p><strong>Document ID:</strong>&nbsp;L0C04CQ4G</p></body></html>